ecampus

GlaxoSmithKline (NYSE: GSK) has changed the Paxil® ( Paxil(Paroxetine) hydrochloride) labeling to reflect updated epidemiological studies which show that infants born to women who had first trimester exposure to Paxil(Paroxetine) had an increased risk of cardiovascular malformations.
The most common malformations in the studies were ventricular and atrial septal defects.
In [...]

[Read more]

An anti depression medicate has been found to help women by reducing menopausal symptoms such as hot flushes.
The meditate of the drug Paxil(Paroxetine) was funded by its makers GlaxoSmithKline.
Menopausal symptoms are usually treated with hormone replacement medical care, which reduces flushes by 80 to 90percent.
But concerns [...]

[Read more]

A well-known drug used to treat hyperactive children boosts the potency of anotherness drug that reduces Parkinson’s malady symptoms, an Oregon Health & Science University meditate has found.
Scientists at the OHSU Parkinson Center of Oregon found that methylphenidate, known commercially as Ritalin, bolsters the effects of levodopa, a drug converted in [...]

[Read more]

People age 70 and older who continued taking the anti depression medicate that helped them to initially recover from their first episode of depression were 60 percent less likely to experience a new episode of depression over a two-year meditate period than those who stopped taking the medication, according to a meditate [...]

[Read more]

GlaxoSmithKline’s policy is to ensure transparency of the clinical data the company collects on itsmarketed medicines. Specifically, we endorse the PhRMA principles that call for timely publication ofmeaningful trial results.
With regard to clinical trial data on Paroxetine, GSK has already provided data that were collectedduring clinical trials in adolescent and paediatric patients [...]

[Read more]

After direction of paliperidone extended-release (ER) pills, blood levels of the drug were not affected when given with a common anti depression medicate, according to new data presented today at the 160th Annual Meeting of the American Psychiatric Association. Paroxetine, a selective serotonin reuptake inhibitor (SSRI), is an anti depression medicate known to interact [...]

[Read more]

First Melatonergic Agonist Antidepressant Shows Efficacy and Tolerability Benefits Over Existing Therapies –
Valdoxan(reg) (agomelatine), the first melatonergic (MT1 and MT2 receptor) agonist anti depression medicate, is an innovation in the a cure of depression with several advantages over existing a cures according to data presented during the 13th Congress of the Association [...]

[Read more]

H. Lundbeck A/S is pleased to announce the acceptance of Cipralex(R) (escitalopram) in Europe for the a cure of obsessive-compulsive disorder (OCD). The acceptance is based on two pivotal studies demonstrating that Cipralex(R) is effective and well-tolerated in the a cure of OCD with the added benefit of encouraging rates of remission [...]

[Read more]

The use of Paroxetine and otherness anti depression medicate drugs continues to grow by about 10percent annually among children and adolescents, according to a meditate published in the April issue of Psychiatric Services. The meditate profiles trends of prescription anti depression medicate use in children and adolescents using prescription claim information from [...]

[Read more]

Babies exposed to anti depression medicatecalled Selective Serotonin Reuptake Inhibitors (SSRIs) in the womb may be born with withdrawal symptom, suggests a meditate published in this week’s issue of The Lancet. The authors of the meditate conclude that doctors should avoid or cautiously manage the prescribing of these drugs to pregnant women [...]

[Read more]